Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study
ConclusionsCFDC could represent an effective and safe treatment option for CRAB BSI, especially in patients with bacteremic HAP/VAP and frail patients where the risk of acute renal failure during therapy should be avoided.
Source: European Journal of Clinical Microbiology and Infectious Diseases - Category: Microbiology Source Type: research
More News: Acinetobacter | COVID-19 | Infectious Diseases | Microbiology | Pneumonia | Renal Failure | SARS | Septic Shock | Study | Urology & Nephrology